Home  /  Oncology

SKANDA offers a comprehensive range of in vitro Oncology research services aimed at advancing the understanding and treatment of cancer.


Skanda Life Sciences is a leader in oncology research, offering comprehensive pre-clinical services to support drug discovery and development. With a diverse panel of cancer cell lines and advanced in vitro assays, we enable precise evaluation of anticancer agents and personalized medicine approaches. Our in vivo efficacy models, including xenograft and syngeneic models, provide valuable insights into tumor biology and therapeutic responses. Partner with us to accelerate your oncology drug discovery journey and bring innovative treatments to patients in need.
Our discovery chemistry services effectively use AI & cheminformatics for multipara metric optimization, and are backed by strong analytical chemistry support, as well as efficient data and compound management.

Cell Viability Assays

These assays assess the viability and cytotoxicity of cancer cells upon exposure to potential anticancer compounds. Common methods include MTT, MTS, XTT, SRB or CellTiter-Glo assays.

Proliferation Assays

Evaluation of cell proliferation rates allows us to gauge the impact of compounds on cancer cell growth. Techniques like BrdU incorporation or EdU assays are utilized for this purpose.

Apoptosis Assays

Detection and quantification of apoptosis induction in cancer cells following treatment are crucial for understanding the apoptotic mechanisms triggered by candidate compounds. Techniques such as Annexin V staining or TUNEL assays are employed using Flow cytometry or Fluorescence plate reader.

Migration and Invasion Assays

These assays assess the migratory and invasive potential of cancer cells, providing insights into metastatic behaviour. Scratch wound assays, trans well migration assays, or Matrigel invasion assays are commonly used.

Cell Cycle Analysis

Analysis of cell cycle distribution helps in understanding the effects of compounds on cell cycle progression. Flow cytometry-based assays with DNA staining (e.g., propidium iodide) are utilized for this purpose.

Angiogenesis Assays

Evaluation of compounds’ ability to inhibit angiogenesis, a critical process in tumor growth and metastasis, is performed using in vitro tube formation assays or endothelial cell migration assays.

Drug Sensitivity Assays

These assays determine the sensitivity of cancer cells to anticancer drugs or drug combinations, typically through dose-response curves or IC50 determination assays.

Drug Resistance Assays

Mechanisms of drug resistance in cancer cells are investigated using drug-resistant cell lines or patient-derived cells to study their response to anticancer agents.

Clonogenic Assays

The Clonogenic potential of cancer cells following treatment is assessed to evaluate their ability to form colonies.

Target-Specific Assays

Development and utilization of assays specific to molecular targets of interest, such as kinase assays, GPCR assays, protease assays, or receptor binding assays, help assess compound activity and selectivity.